CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-581.6	-366.25	-153.61	-650.18	377.66
Depreciation & Amortization	19.48	19.26	19.84	24.17	17.95
Stock-Based Compensation	72.5	86.57	81.03	97.95	102.39
Other Adjustments	72.73	-38.62	-14.05	12.47	14.11
Change in Receivables	25	175	-200	0.31	-0.16
Changes in Accounts Payable	44.89	-27.28	-20.25	5.16	37.51
Changes in Unearned Revenue	-0.4	-1.95	5.79	-1.01	-0.78
Changes in Other Operating Activities	2.39	10.5	20.87	15.39	-9.71
Operating Cash Flow	-345.01	-142.77	-260.38	-495.74	538.97
Capital Expenditures	-0.91	-1.9	-9.47	-37.19	-81.71
Purchases of Intangible Assets	-25	-	-2.5	-	-
Purchases of Investments	-1,018	-1,486	-1,066	-1,418	-1,509
Proceeds from Sale of Investments	1,012	1,208	1,453	1,196	555.6
Investing Cash Flow	-31.81	-280.48	374.65	-258.66	-1,035
Issuance of Common Stock	426.03	331.98	62.66	38.59	250.95
Net Common Stock Issued (Repurchased)	426.03	331.98	62.66	38.59	250.95
Financing Cash Flow	426.03	331.98	62.66	38.59	250.95
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.1	-0.02	0.07	-0.08	-0.01
Net Cash Flow	49.3	-91.29	177.01	-715.88	-245.52
Free Cash Flow	-345.93	-144.68	-269.85	-532.93	457.27
FCF Margin	-9855.50%	-387.72%	-72.69%	-44484.89%	49.98%
Free Cash Flow Per Share	-3.85	-1.71	-3.41	-6.85	5.69
Levered Free Cash Flow	-516.15	-367.62	-136.83	-643.65	340.93
Unlevered Free Cash Flow	-604.04	-474.41	-213.9	-666.99	338.61

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q